Assessing the public health impact of tolerance-based therapies with mathematical models

Disease tolerance is a defense strategy against infections that aims at maintaining host health even at high pathogen replication or load. Tolerance mechanisms are currently intensively studied with the long-term goal of exploiting them therapeutically. Because tolerance-based treatment imposes less selective pressure on the pathogen it has been hypothesised to be “evolution-proof”. However, the primary public health goal is to reduce the incidence and mortality associated with a disease. From this perspective, tolerance-based treatment bears the risk of increasing the prevalence of the disease, which may lead to increased mortality. We assessed the promise of tolerance-based treatment strategies using mathematical models. Conventional treatment was implemented as an increased recovery rate, while tolerance-based treatment was assumed to reduce the disease-related mortality of infected hosts without affecting recovery. We investigated the endemic phase of two types of infections: acute and chronic. Additionally, we considered the effect of pathogen resistance against conventional treatment. We show that, for low coverage of tolerance-based treatment, chronic infections can cause even more deaths than without treatment. Overall, we found that conventional treatment always outperforms tolerance-based treatment, even when we allow the emergence of pathogen resistance. Our results cast doubt on the potential benefit of tolerance-based over conventional treatment. Any clinical application of tolerance-based treatment of infectious diseases has to consider the associated detrimental epidemiological feedback.

[1]  Hilla Peretz,et al.  The , 1966 .

[2]  M. Baalen Coevolution of recovery ability and virulence , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[3]  M. Totsika,et al.  Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era , 2016, Current Medicinal Chemistry.

[4]  S. Molin,et al.  Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. , 2004, The Journal of antimicrobial chemotherapy.

[5]  P. Thrall,et al.  The cost of resistance and the maintenance of genetic polymorphism in host—pathogen systems , 1994, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[6]  A. Best,et al.  THE COEVOLUTIONARY IMPLICATIONS OF HOST TOLERANCE , 2014, Evolution; international journal of organic evolution.

[7]  J. Koella,et al.  Concurrent Evolution of Resistance and Tolerance to Pathogens , 2004, The American Naturalist.

[8]  M. Hadjifrangiskou,et al.  The arsenal of pathogens and antivirulence therapeutic strategies for disarming them , 2016, Drug design, development and therapy.

[9]  Marc Choisy,et al.  Host nutrition alters the variance in parasite transmission potential , 2013, Biology Letters.

[10]  D. Green,et al.  Anthracyclines induce DNA damage response-mediated protection against severe sepsis. , 2013, Immunity.

[11]  Sylvain Gandon,et al.  Imperfect vaccines and the evolution of pathogen virulence , 2001, Nature.

[12]  A. Coutinho,et al.  Heme oxygenase-1 affords protection against noncerebral forms of severe malaria , 2009, Proceedings of the National Academy of Sciences.

[13]  M. van Baalen Coevolution of recovery ability and virulence. , 1998, Proceedings. Biological sciences.

[14]  M. Begon,et al.  Life-history trade-offs and the evolution of pathogen resistance: competition between host strains , 1994, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[15]  K. P. Murphy,et al.  Janeway's immunobiology , 2007 .

[16]  A. White,et al.  The role of ecological feedbacks in the evolution of host defence: what does theory tell us? , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[17]  A. White,et al.  THE EVOLUTION OF PARASITES IN RESPONSE TO TOLERANCE IN THEIR HOSTS: THE GOOD, THE BAD, AND APPARENT COMMENSALISM , 2006, Evolution; international journal of organic evolution.

[18]  S. Plotkin,et al.  Microbial evolution (Communication arising): Antitoxin vaccines and pathogen virulence , 2002, Nature.

[19]  R. Bowers,et al.  The evolution of resistance through costly acquired immunity , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[20]  A. Read,et al.  Animal Defenses against Infectious Agents: Is Damage Control More Important Than Pathogen Control? , 2008, PLoS biology.

[21]  V. Sperandio,et al.  Anti-virulence strategies to combat bacteria-mediated disease , 2010, Nature Reviews Drug Discovery.

[22]  R. Bowers,et al.  Three mechanisms of host resistance to microparasites-avoidance, recovery and tolerance-show different evolutionary dynamics. , 1999, Journal of theoretical biology.

[23]  Herbert W. Hethcote,et al.  The Mathematics of Infectious Diseases , 2000, SIAM Rev..

[24]  Lars Råberg,et al.  Decomposing health: tolerance and resistance to parasites in animals , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[25]  David S Schneider,et al.  Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases , 2008, Nature Reviews Immunology.

[26]  Sam P. Brown,et al.  Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics , 2014, PLoS biology.

[27]  I. Bechmann,et al.  Sickle Hemoglobin Confers Tolerance to Plasmodium Infection , 2011, Cell.

[28]  J. Kirchner,et al.  EVOLUTIONARY DYNAMICS OF PATHOGEN RESISTANCE AND TOLERANCE , 2000, Evolution; international journal of organic evolution.

[29]  N. Sepúlveda,et al.  A Central Role for Free Heme in the Pathogenesis of Severe Sepsis , 2010, Science Translational Medicine.

[30]  K. Starko,et al.  Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Joshua E. Elias,et al.  Role of disease-associated tolerance in infectious superspreaders , 2014, Proceedings of the National Academy of Sciences.

[32]  C. Sweet,et al.  Elevation of nasal viral levels by suppression of fever in ferrets infected with influenza viruses of differing virulence. , 1982, The Journal of infectious diseases.

[33]  R. Munford,et al.  Novel therapies for septic shock over the past 4 decades. , 2011, JAMA.

[34]  A. Best,et al.  Maintenance of host variation in tolerance to pathogens and parasites , 2008, Proceedings of the National Academy of Sciences.

[35]  Stephen P. Diggle,et al.  Targeting virulence: can we make evolution-proof drugs? , 2014, Nature Reviews Microbiology.

[36]  D. Earn,et al.  Population-level effects of suppressing fever , 2014, Proceedings of the Royal Society B: Biological Sciences.

[37]  P. Kaye Infectious diseases of humans: Dynamics and control , 1993 .

[38]  J. Koella,et al.  Shared Control of Epidemiological Traits in a Coevolutionary Model of Host‐Parasite Interactions , 2003, The American Naturalist.

[39]  Charles Flexner,et al.  HIV drug development: the next 25 years , 2007, Nature Reviews Drug Discovery.

[40]  Ruslan Medzhitov,et al.  Disease Tolerance as a Defense Strategy , 2012, Science.

[41]  W. O. Kermack,et al.  A contribution to the mathematical theory of epidemics , 1927 .